# RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

> **NCT01071564** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Estrogen Receptor Negative
- HER2/Neu Negative
- Progesterone Receptor Negative
- Recurrent Breast Carcinoma
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Gamma-Secretase Inhibitor RO4929097
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacogenomic Study
- **OTHER:** Pharmacological Study
- **DRUG:** Vismodegib

## Key facts

- **NCT ID:** NCT01071564
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2015-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01071564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01071564, "RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01071564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*